Analysts Set Expectations for ITOS FY2029 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – HC Wainwright issued their FY2029 EPS estimates for shares of iTeos Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn $1.19 per share for the year. HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.13.

Other analysts also recently issued reports about the stock. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday. Wells Fargo & Company decreased their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock opened at $7.05 on Friday. The firm has a market cap of $257.56 million, a PE ratio of -2.24 and a beta of 1.38. The firm’s 50 day moving average price is $7.52 and its two-hundred day moving average price is $9.42. iTeos Therapeutics has a twelve month low of $6.67 and a twelve month high of $18.75.

Institutional Trading of iTeos Therapeutics

Several large investors have recently modified their holdings of the company. BVF Inc. IL bought a new stake in shares of iTeos Therapeutics during the 4th quarter worth $17,856,000. JPMorgan Chase & Co. boosted its holdings in shares of iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock worth $15,888,000 after buying an additional 1,601,477 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after buying an additional 163,880 shares during the period. State Street Corp boosted its holdings in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after buying an additional 211,452 shares during the period. Finally, Boxer Capital Management LLC bought a new stake in shares of iTeos Therapeutics during the 4th quarter worth $7,272,000. 97.16% of the stock is owned by institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.